2025-520452-28-00招募中2 期
Fecal microbiota transfer for the secondary prevention of recurrent urinary tract infections in premenopausal women: a phase II trial (FEMITRANS)
Goethe University Frankfurt3 个研究点 分布在 1 个国家目标入组 24 人开始时间: 2025年5月22日最近更新:
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 发起方
- 入组人数
- 24
- 试验地点
- 3
- 主要终点
- Rate of new UTI episodes within 180 days after treatment. A UTI for the endpoint assessment is defined as presence of at least one typical symptom (dysuria, alguria, pollakiuria or flank pain) in the absence of alternative causes plus the detection of a typical or potential uropathogen as defined by protocol by urinary culture.
研究概览
简要总结
Assessment of the clinical efficacy of fecal microbiota transfer (FMT) in the prevention of rUTI episodes and investigation of donor and recipient microbiota factors that determine treatment success of FMT
入排标准
- 年龄范围
- 18 years 至 64 years（18-64 Years）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •Premenopausal adult women with recent history of rUTI defined as ≥ four UTI during the last 12 months. A UTI is defined as presence of at least one typical symptom (dysuria, alguria, pollakiuria or flank pain) in the absence of alternative causes.
- •Unsuccessful secondary prophylaxis of rUTI by lifestyle modifications including increased water intake and postcoital voiding
- •Last acute symptomatic UTI episode confirmed by urinary culture and caused by either Escherichia coli or Klebsiella pneumoniae susceptible to fosfomycin
- •Written informed consent obtained according to international guidelines and local laws
- •Ability to understand the nature of the trial and the trial related procedures and to comply with them
排除标准
- •Inability to swallow 30 FMT capsules and undergo bowel lavage
- •Known phenylketonuria or glucose-6-phosphate dehydrogenase deficiency
- •Known allergy, hypersensitivity or intolerance to any of the used investigational medicinal products
- •Planned or ongoing intake of prohibited concomitant medication as per protocol
- •Currently enrolled in another interventional trial
- •Failure to use one of the following safe methods of contraception: female condoms, diaphragm or coil, each used in combination with spermicides; intra-uterine device; hormonal contraception in combination with a mechanical method of contraception; e.g. Women can only take part in this study if the risk of becoming pregnant is absolutely minimized. Save contraceptive methods comprise: female condoms, diaphragm or coil, each used in combination with spermicides; intra-uterine device; hormonal contraception in combination with a mechanical method of contraception and have to be used while participating in the study; (see section 7.5.3).
- •Other conditions that according to the investigator might interfere with the evaluation of study objectives or patient safety.
- •Known anatomical or functional abnormalities in the lower urinary tract including neurogenic bladder and incontinence
- •Modifiable risk factors for rUTI (e.g. uncontrolled diabetes mellitus)
- •Current pregnancy
- •Uncontrolled inflammatory bowel disease (e.g. ulcerative colitis or Crohn's disease) defined as the necessity to start or modify immunosuppressive treatment within the preceding three months due to disease activity.
- •Presence of severe intestinal inflammation due to other cause
- •Advanced stage chronic heart failure (NYHA III/IV)
- •Gastrointestinal perforation, obstruction, ileus or retention of gastric contents
- •Severe immunosuppression defined as at least one of the following: (a) patients with current or foreseeable neutropenia within the 14 days of study treatment (defined as <500 neutrophils/ml) (b) patients scheduled for or having received CAR-T-cell therapy or allogeneic stem cell transplantation (SCT) or solid organ transplantation within 100 days prior or after enrolment (c) patients with active graft versus host disease or allograft rejection requiring intensified immunosuppressive treatment (d) patients treated with corticosteroids equivalent to prednisone ≥20 mg daily for 14 consecutive days prior or after enrollment (e) patients with HIV infection with CD4+ cell count <200/mm³ within the past 3 months of screening
结局指标
主要结局
Rate of new UTI episodes within 180 days after treatment. A UTI for the endpoint assessment is defined as presence of at least one typical symptom (dysuria, alguria, pollakiuria or flank pain) in the absence of alternative causes plus the detection of a typical or potential uropathogen as defined by protocol by urinary culture.
Rate of new UTI episodes within 180 days after treatment. A UTI for the endpoint assessment is defined as presence of at least one typical symptom (dysuria, alguria, pollakiuria or flank pain) in the absence of alternative causes plus the detection of a typical or potential uropathogen as defined by protocol by urinary culture.
次要结局
- Time to Post-FMT UTI: time to first UTI episode after treatment
- Symptom burden: mean changes in ACSS score values on Day 7, 30, 90 and 180 compared to Baseline.
- Quality of Life: mean changes in score values on Day 30, 90 and 180 compared to Baseline
- Number of new UTI episodes within 180 days after treatment caused by the same uropathogen as the last episode prior treatment
- Antibiotic treatment frequency: Number of rUTI episodes treated with antibiotic until day 180
- Vaginal infections: Number of episodes of bacterial vaginosis and/or candidosis until day 180
- Assessment of safety: comparison of safety data between patients with or without FMT via review of nature, frequency and severity of adverse events (AEs), serious AEs (SAEs), and new medical conditions during six- month follow-up period
研究者
Maria Vehreschild
Scientific
Goethe University Frankfurt
研究点 (3)
Loading locations...
相似试验
招募中
2 期
Fecal Microbiota Transplantation to RESCUE Patients With Unresectable Hcc Progressors to First Line Therapy With AtezolizUmaB and BevacizumabNCT07276100IRCCS Azienda Ospedaliero-Universitaria di Bologna15
招募中
2 期
Fecal Microbiota Transplantation to RESCUE patients with unresectable Hcc progressors to first line therapy with AtezolizUmaB and Bevacizumab (RESCUE-HUB)2023-510504-45-00Azienda Ospedaliero-Universitaria Di Bologna IRCCS Istituto Di Ricerca E Di Cura A Carattere Scientifico15
招募中
不适用
Real-World Study on Fecal Microbiota Transplantation: Long-Term Effectiveness and Safety StatisticsAutism Spectrum DisorderNCT07261826Chen QiYi4,000
已完成
2 期
Efficacy and Safety of Fecal Microbiota Transfer (FMT) for Recurrent Urinary Tract Infections in WomenNCT07194941Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal40
已完成
2 期
FMT in IT-refractory HCC - FAB-HCC Pilot StudyHepatocellular Carcinoma2024-516835-29-00Medical University Of Vienna12